F S&P 500
5,334.50 +7.25 (+0.14%) F Dow Jones
40,180.00 +43.00 (+0.11%) F Nasdaq
18,661.50 +26.25 (+0.14%) E-mini Russell 2000 Index Futur
2,110.00 +4.50 (+0.21%) Petróleo
79.86 -0.20 (-0.25%) Oro
2,423.50 +6.10 (+0.25%)
Monte Rosa Therapeutics, Inc. (GLUE)
Fuera de horario:
Monte Rosa Therapeutics, Inc.
321 Harrison Avenue
Suite 900
Boston, MA 02118
United States
(617) 949-2643
https://www.monterosatx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 130
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Markus Warmuth M.D. | President, CEO & Director | 924.6k | N/D | 1971 |
| Dr. Filip Janku M.D., Ph.D. | Chief Medical Officer | 713.2k | N/D | 1974 |
| Ms. Jennifer Champoux | Chief People & Operations Officer | N/D | N/D | N/D |
| Dr. Sharon Townson Ph.D. | Chief Technology Officer | N/D | N/D | 1975 |
| Dr. John C. Castle Ph.D. | Chief Data & Information Officer | N/D | N/D | 1972 |
| Mr. Andrew Funderburk | Senior VP and Head of IR & Strategic Finance | N/D | N/D | N/D |
| Mr. Philip Nickson J.D., Ph.D. | General Counsel | N/D | N/D | 1979 |
| Mr. Magnus Walter DPHIL | Senior Vice President of Drug Discovery | N/D | N/D | N/D |
| Mr. Edmund Dunn | Vice President & Corporate Controller | N/D | N/D | 1966 |
Descripción
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Gestión corporativa
La calificación ISS Governance QuickScore de Monte Rosa Therapeutics, Inc. a partir del 1 de mayo de 2024 es 9. Las puntuaciones principales son Auditoría: 9; Junta: 9; Derechos del accionista: 8; Compensación: 8.
